AntibioticDB

GSK656, GSK3036656, Ganfeborole

Aminoacyl-tRNA synthetase inhibitor (leucyl-tRNA synthetase [LeuRs] inhibitor)

GSK, USA

2019

Highest development stage: Phase 2
Mechanism of Action/Target pathogen: Active against <i>Mycobacterium tuberculosis</i> and <i>M. abscessus</i>
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=12796
Source: https://aac.asm.org/content/64/2/e01577-19
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/133080621